PMID

Data

Article Title

Organization

SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.

Central Pharmaceutical Research Institute

Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors.

Central Pharmaceutical Research Institute

Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.

Central Pharmaceutical Research Institute

Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.

Central Pharmaceutical Research Institute

Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.

Central Pharmaceutical Research Institute

Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.

Central Pharmaceutical Research Institute

4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).

Central Pharmaceutical Research Institute

Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.

Central Pharmaceutical Research Institute

New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists.

Central Pharmaceutical Research Institute

Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.

Central Pharmaceutical Research Institute

Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.

Central Pharmaceutical Research Institute

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.

Central Pharmaceutical Research Institute

Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole.

Central Pharmaceutical Research Institute

Structure-based drug design of novel and highly potent pyruvate dehydrogenase kinase inhibitors.

Central Pharmaceutical Research Institute

S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.

Central Pharmaceutical Research Institute

New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.

Central Pharmaceutical Research Institute

Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.

Central Pharmaceutical Research Institute

4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors.

Central Pharmaceutical Research Institute

4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.

Central Pharmaceutical Research Institute

Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models.

Central Pharmaceutical Research Institute